Personalis, Inc. (NASDAQ: PSNL)

Personalis, Inc. develops markets and sells advanced cancer genomic testing services. The company operates in the precision oncology diagnostics industry providing tumor informed liquid biopsy tests comprehensive tumor profiling assays immuno oncology tissue based tests and whole exome and genome sequencing services for diagnostics companies and population sequencing initiatives.

Personalis, Inc. generates revenue primarily from the sale of its cancer genomic testing services to pharmaceutical and biopharmaceutical companies diagnostics companies universities non profits government entities and cancer patients. The company offers NeXT Personal Dx for minimal residual disease detection and recurrence monitoring NeXT Dx for comprehensive tumor profiling ImmunoID NeXT for immuno oncology tissue based analysis whole exome sequencing for diagnostic partners and whole genome sequencing for population sequencing initiatives. Revenue also stems from collaborative agreements such as the co commercialize arrangement with Tempus and from Medicare reimbursement for certain indications.

The company operates through the following segments.

• The Advanced Cancer Genomic Testing Services segment provides tumor informed liquid biopsy testing for minimal residual disease detection and recurrence monitoring through the NeXT Personal Dx assay which includes a Real Time Variant Tracker feature for reporting resistance associated and targetable mutations. The segment also offers NeXT Dx a comprehensive tumor profiling test that analyzes exome and transcriptome to support therapy selection and clinical trial identification. Additionally it supplies ImmunoID NeXT a tissue based test that combines exome and transcriptome data to characterize the tumor microenvironment and identify neoantigens for personalized immunotherapy. The segment further delivers whole exome sequencing services for diagnostic companies and whole genome sequencing services for population sequencing initiatives. All testing is performed in a CLIA certified CAP accredited high complexity laboratory located in Fremont California.

Personalis, Inc. competes in the cancer diagnostics market against companies such as Adela Inc Caris Life Sciences Inc DELFI Diagnostics Inc Exact Sciences Corporation Foresight Diagnostics Inc Foundation Medicine Inc GRAIL Inc Guardant Health Inc Haystack Oncology Inc Laboratory Corporation of America Holdings MedGenome Inc Myriad Genetics Inc Natera NeoGenomics Inc Predicine Inc SAGA Diagnostics AB and Veracyte Inc. The company differentiates itself through its ultrasensitive MRD detection capability that can identify cancer recurrence months before imaging its comprehensive genomic data reporting its high quality results and its responsive customer service. These strengths allow Personalis to gain traction with pharmaceutical partners seeking reliable biomarkers and with clinicians aiming to guide treatment decisions.

Personalis, Inc. serves a diverse customer base that includes global pharmaceutical and biopharmaceutical companies diagnostics companies universities non profits government entities and individual cancer patients. Specific customers that have contributed significant revenue include Moderna the VA MVP Natera and Tempus. The company also collaborates with numerous academic medical centers such as Cancer Research UK University College London the Francis Crick Institute Institut Curie the Royal Marsden Vall d'Hebron Institute of Oncology the University of California San Diego Duke University Vanderbilt University Johns Hopkins University Dana Farber Cancer Institute the University of Texas M D Anderson Cancer Center University Medical Center Hamburg Eppendorf Criterium the Academic Breast Cancer Consortium Yale Cancer Center Aarhus University British Columbia Cancer and University Health Network.